Table 2.
Primary care-led investigations ordered by the GP as part of the diagnostic assessment prior to referral by gender and cancer site in the 2018 audit (n = 62 559)a
| Investigation group, n (%) | Patients investigated by test type, n (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Noneb | Any | Not known | Blood | Urinary | Imaging | Endoscopy | Symptomatic FIT | Other | |
| Total | 32 592 (52.1) | 29 967 (47.9) | 1930 | 23 443 (37.5) | 856 (1.4) | 12 377 (19.8) | 849 (1.4) | 104 (0.2) | 1793 (2.9) |
|
| |||||||||
| Gender | |||||||||
| Male | 13 132 (40.6) | 19 236 (59.4) | 992 | 15 876 (49.0) | 605 (1.9) | 6444 (19.9) | 475 (1.5) | 57 (0.2) | 1042 (3.2) |
| Female | 19 460 (64.5) | 10 731 (35.5) | 938 | 7567 (25.1) | 251 (0.8) | 5933 (19.7) | 374 (1.2) | 47 (0.2) | 751 (2.5) |
|
| |||||||||
| Cancer | |||||||||
| Bladder | 643 (39.7) | 977 (60.3) | 50 | 603 (37.2) | 238 (14.7) | 215 (13.3) | 10 (0.6) | 1 (0.1) | 253 (15.6) |
| Brain | 658 (76.5) | 202 (23.5) | 28 | 154 (17.9) | 7 (0.8) | 83 (9.7) | 1 (0.1) | 0 (0.0) | 13 (1.5) |
| Breast | 9208 (96.0) | 384 (4.0) | 262 | 245 (2.6) | 3 (0.0) | 193 (2.0) | 5 (0.1) | 2 (0.0) | 29 (0.3) |
| CUP | 582 (47.2) | 651 (52.8) | 59 | 515 (41.8) | 12 (1.0) | 376 (30.5) | 15 (1.2) | 2 (0.2) | 29 (2.4) |
| Colon | 2039 (44.9) | 2499 (55.1) | 115 | 2297 (50.6) | 28 (0.6) | 660 (14.5) | 155 (3.4) | 40 (0.9) | 145 (3.2) |
| Endometrial | 905 (55.5) | 726 (44.5) | 36 | 388 (23.8) | 29 (1.8) | 467 (28.6) | 7 (0.4) | 2 (0.1) | 90 (5.5) |
| Leukaemia | 541 (35.0) | 1005 (65.0) | 44 | 972 (62.9) | 11 (0.7) | 185 (12.0) | 6 (0.4) | 1 (0.1) | 30 (1.9) |
| Liver | 475 (48.6) | 502 (51.4) | 35 | 425 (43.5) | 9 (0.9) | 301 (30.8) | 18 (1.8) | 2 (0.2) | 11 (1.1) |
| Lung | 3438 (43.5) | 4460 (56.5) | 233 | 2238 (28.3) | 23 (0.3) | 3877 (49.1) | 70 (0.9) | 6 (0.1) | 163 (2.1) |
| Lymphoma | 1059 (42.8) | 1415 (57.2) | 91 | 1086 (43.9) | 11 (0.4) | 810 (32.7) | 28 (1.1) | 2 (0.1) | 51 (2.1) |
| Melanoma | 2711 (92.8) | 210 (7.2) | 48 | 62 (2.1) | 0 (0.0) | 35 (1.2) | 0 (0.0) | 1 (0.0) | 129 (4.4) |
| Multiple myeloma | 299 (31.8) | 641 (68.2) | 32 | 590 (62.8) | 9 (1.0) | 257 (27.3) | 11 (1.2) | 0 (0.0) | 13 (1.4) |
| Oesophageal | 748 (51.1) | 716 (48.9) | 31 | 576 (39.3) | 2 (0.1) | 171 (11.7) | 152 (10.4) | 2 (0.1) | 34 (2.3) |
| Oral/oropharyngeal | 888 (74.6) | 302 (25.4) | 51 | 198 (16.6) | 1 (0.1) | 180 (15.1) | 3 (0.3) | 0 (0.0) | 22 (1.8) |
| Other | 3227 (53.4) | 2814 (46.6) | 270 | 1704 (28.2) | 70 (1.2) | 1823 (30.2) | 51 (0.8) | 6 (0.1) | 211 (3.5) |
| Ovarian | 394 (34.9) | 734 (65.1) | 21 | 576 (51.1) | 12 (1.1) | 511 (45.3) | 19 (1.7) | 2 (0.2) | 33 (2.9) |
| Pancreatic | 638 (36.1) | 1127 (63.9) | 55 | 984 (55.8) | 23 (1.3) | 560 (31.7) | 64 (3.6) | 4 (0.2) | 51 (2.9) |
| Prostate | 1662 (17.4) | 7865 (82.6) | 312 | 7632 (80.1) | 297 (3.1) | 793 (8.3) | 20 (0.2) | 1 (0.0) | 245 (2.6) |
| Rectal | 1179 (50.7) | 1147 (49.3) | 68 | 1056 (45.4) | 5 (0.2) | 132 (5.7) | 87 (3.7) | 23 (1.0) | 99 (4.3) |
| Renal | 899 (49.2) | 930 (50.8) | 65 | 580 (31.7) | 64 (3.5) | 574 (31.4) | 20 (1.1) | 4 (0.2) | 91 (5.0) |
| Stomach | 399 (37.7) | 660 (62.3) | 24 | 562 (53.1) | 2 (0.2) | 174 (16.4) | 107 (10.1) | 3 (0.3) | 51 (4.8) |
a
Not known values have been excluded from percentage calculations. This is to prevent under-reporting of the proportion of the known categories by assuming that the not known cases are missing at random and therefore evenly distributed among the known groups.
b
Screening and not applicable cases are included in the ‘None’ investigations category. CUP = cancer of unknown primary. FIT = faecal immunochemical test.